inside tracker
inside tracker

Longevity TV

Investing in the age of Longevity: Investment panel

The Longevity Week: Master Investor Masterclass The Investment Panel investigates demonstrated Longevity growth, name-checking some hot areas for investment, seeing how Longevity-ready institutional investors are...

Investing in the age of Longevity: Science panel

The Longevity Week: Master Investor Masterclass It was the Longevity Forum's Longevity Week this week and this Science Panel, supported by Master Investor, benchmarks current...

Startup Showcase: Rejuvenate Biomed: What do you think?

Rejuvenate Biomed are ready to take their first Longevity therapy into clinical trials: Invest, buy, or both? It's time to have your say on...

Exclusive video interview with Dave Asprey

We talk supplementation, neurotech, mitochondrial dysfunction, clinical scale-ups, COVID and CGM with Longevity legend: Dave Asprey Ahead of Revolution Against Aging and Death conference, which...

Startup Showcase: Jinfiniti: What do you think?

Comprehensive biomarker tech: Invest, buy, or both? It's time to have your say on Jinfiniti. We like what Jinfiniti are doing; but that's just our...

Exclusive video interview: David Wood demystifies the transhumanist agenda

As Longevity moves quickly into the mainstream there are terms and legacies that some use to challenge the sector's validity: we explore what it...

The Big Picture: Covid-19 and Longevity investing

Jim Mellon, Chairman and Founder, Burnbrae Group

Video interview: talking senescence with Nina Khera

Teenage founder of Canadian start-up Biotein hunts a universal phenotype for senescent cells. As we’ve covered in the past, Biotein’s Nina Khera has a mission...

Video interview with BioViva’s Liz Parrish

BioViva and Integrated Health Systems: How many patients in trials? Where are they located? What pipeline stage? As we've covered in the past, BioViva's Liz...

Video interview with Dr Isabelle Schiffer on senolytic safety

Forever Healthy Foundation issues risk-benefit analysis on dasatinib + quercetin as a senolytic. The Forever Healthy Foundation published its latest risk-benefit analysis, which explores the combined...
inside tracker
lumen

Latest articles